Conflict of interest: M. W. is a consultant for and stockholder in Photothera and J. Z. is a consultant for Photothera.
Transcranial laser therapy for acute ischemic stroke: a pooled analysis of NEST-1 and NEST-2
Article first published online: 2 FEB 2012
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization
International Journal of Stroke
Volume 8, Issue 5, pages 315–320, July 2013
How to Cite
Huisa, B. N., Stemer, A. B., Walker, M. G., Rapp, K., Meyer, B. C., Zivin, J. A. and NEST-1 and -2 investigators (2013), Transcranial laser therapy for acute ischemic stroke: a pooled analysis of NEST-1 and NEST-2. International Journal of Stroke, 8: 315–320. doi: 10.1111/j.1747-4949.2011.00754.x
Source of funding: Partial funding through NIH grant (3P50 NSO44148-07S2)
NEST-1 and -2 were supported by PhotoThera, Inc, Carlsbad, California.
Disclosures: B. H., A. S., K. R., and B. M. have nothing to disclose.
M. W. is a consultant for and stockholder in Photothera and J. Z. is a consultant for Photothera.
- Issue published online: 20 JUN 2013
- Article first published online: 2 FEB 2012
- NIH. Grant Number: 3P50 NSO44148-07S2
- acute stroke;
- clinical trial;
- laser therapy;
- stroke outcomes
NeuroThera Effectiveness and Safety Trials (NEST) 1 and 2 have demonstrated safety of transcranial laser therapy (TLT) for human treatment in acute ischemic stroke. NEST 1 study suggested efficacy of TLT but the following NEST 2, despite strong signals, missed reaching significance on its primary efficacy endpoint. In order to assess efficacy in a larger cohort, a pooled analysis was therefore performed.
The two studies were first compared for heterogeneity, and then a pooled analysis was performed to assess overall safety and efficacy, and examined particular subgroups. The primary endpoint for the pooled analysis was dichotomized modified Rankin scale (mRS) 0–2 at 90 days.
Efficacy analysis for the intention-to-treat population was based on a total of 778 patients. Baseline characteristics and prognostic factors were balanced between the two groups. The TLT group (n = 410) success rate measured by the dichotomized 90-day mRS was significantly higher compared with the sham group (n = 368) (P = 0·003, OR: 1·67, 95% CI: 1·19–2·35). The distribution of scores on the 90-day mRS was significantly different in TLT compared with sham (P = 0·0005 Cochran–Mantel–Haenszel). Subgroup analysis identified moderate strokes as a predictor of better treatment response.
This pooled analysis support the likelihood that transcranial laser therapy is effective for the treatment of acute ischemic stroke when initiated within 24 h of stroke onset. If ultimately confirmed, transcranial laser therapy will change management and improve outcomes of far more patients with acute ischemic stroke.